<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>JAMA: Oncology Topic Collection</title>
    <link>http://jama.jamanetwork.com/</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Wed, 15 May 2013 00:00:00 GMT</pubDate>
    <lastBuildDate>Tue, 14 May 2013 20:45:24 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>editor@jama.jamanetwork.com</managingEditor>
    <webMaster>webmaster@jama.jamanetwork.com</webMaster>
    <item>
      <title>Cost Consequences of the 340B Drug Discount Program Cost Consequences of the 340B Drug Discount Program </title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=1680369</link>
      <pubDate>Wed, 15 May 2013 00:00:00 GMT</pubDate>
      <author>Conti RM, Bach PB. </author>
      <description>&lt;span class="paragraphSection"&gt;Created in 1992, a little-known federal drug discount program called “340B” allowed a handful of hospitals that cared for the poor to obtain drugs for their patients at substantially reduced prices. Today, through a series of expansions, including some enumerated in the Affordable Care Act, numerous other types of entities such as community hospitals and cancer centers that serve both the poor and the well-insured can participate. Between 2009 and 2012 the number of enrolled hospitals doubled, and today the program includes 1679 hospitals, a third of all hospitals in the United States.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">309</prism:volume>
      <prism:number xmlns:prism="prism">19</prism:number>
      <prism:startingPage xmlns:prism="prism">1995</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">1996</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2013.4156</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=1680369</guid>
    </item>
  </channel>
</rss>